- Pain experts to discuss trends in kappa opioid receptor agonists and the future of postoperative pain management
- Company to present positive data from Phase 2 acute pain trials of I.V. CR845 in poster session
SHELTON, Conn., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will sponsor a satellite symposium titled "Kappa Opioid Receptor Agonists (KORAs) - Moving Beyond Mu in Post-Operative Care" at ANESTHESIOLOGY 2015, the American Society of Anesthesiologists' annual meeting, which will be held in San Diego, California. Leading pain experts will discuss the latest developments in postoperative analgesic care, including results from multiple Phase 2 studies of I.V. CR845 in acute postoperative pain. CR845 is the Company's first-in-class peripherally selective kappa opioid agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
The symposium details are as follows:
Date: Monday, October 26, 2015
Time: 6:30-8:00 a.m. PT
Location: Grand Hall A, Manchester Grand Hyatt, San Diego, CA
- Tong J. Gan, M.D., M.H.S., F.R.C.A., Professor and Chairman, Department of Anesthesiology, Stony Brook Medicine
- Keith A. Candiotti, M.D., Executive Vice Chair & Chief Operating Officer, Professor of Clinical Anesthesiology, Vice Chair of Clinical Research and Chief, Division Perioperative Medicine, University of Miami
- Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics; Assistant Professor, Department of Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine
In addition, Dr. Stauffer will present data from three of Cara's Phase 2 studies of I.V. CR845 during the following poster session:
Title: "CR845, A Novel Peripherally-Acting Kappa Opioid Receptor Agonist, Provides Post-Operative Analgesia as Well as Reduces Post-Operative Nausea and Vomiting"
Poster Number: A3209 / Monitor 17
Location: Hall B2, Area E, San Diego Convention Center
Date: Monday, October 26, 2015
Time: 3:45 to 4:15 p.m. PT
For more information on ANESTHESIOLOGY 2015, visit: https://www.asahq.org/annual%20meeting.
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara recently initiated its Phase 3 program with I.V. CR845 in postoperative pain. Cara also has an ongoing Phase 2 trial of an oral tablet formulation of CR845, for the treatment of osteoarthritis (OA).
In Q3'15, Cara announced positive results with I.V. CR845 in a Phase 2 trial in uremic pruritus patients where CR845 treatment resulted in statistically significant reductions in both the primary endpoint of worst itching and secondary endpoints assessing quality of life measurements.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.